Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 7/20 | 0.55 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | SMYD3 | Q9H7B4 | 9/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | STAT1 | P42224 | 2/20 | 0.50 |
| ▸ | STAT3 | P40763 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28161316 | 0.98 | S1PR3 (0.54) | S1PR3S1PR1NPC1RAB9ASMYD3 | |
| SCHEMBL2799260 | 0.93 | S1PR3 (0.60) | S1PR3S1PR1NPC1RAB9ASMYD3 | |
| SCHEMBL21317622 | 0.91 | S1PR3 (0.63) | S1PR3S1PR1NPC1RAB9ASMYD3 | |
| SCHEMBL2799191 | 0.91 | S1PR3 (0.63) | S1PR3S1PR1NPC1RAB9ASMYD3 | |
| SCHEMBL2797162 | 0.90 | S1PR3 (0.55) | S1PR3S1PR1NPC1RAB9ASMYD3 | |
| SCHEMBL31643938 | 0.85 | S1PR3 (0.42) | S1PR3S1PR1NPC1RAB9ASMYD3 | |
| SCHEMBL28856869 | 0.84 | S1PR3 (0.58) | S1PR3S1PR1NPC1RAB9ASMYD3 | |
| SCHEMBL841342 | 0.82 | S1PR3 (0.57) | S1PR3S1PR1NPC1RAB9ASMYD3 | |
| SCHEMBL11721317 | 0.81 | RAB9A (0.60) | NPC1RAB9ASMYD3TSHRSTAT1 | |
| SCHEMBL13835610 | 0.81 | RAB9A (0.56) | S1PR3S1PR1NPC1RAB9ASMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3600312-B1 | PIPERIDINYL- AND PIPERAZINYL-SUBSTITUTED HETEROAROMATIC CARBOXAMIDES AS MODULATORS OF GPR6 | TAKEDA PHARMACEUTICALS CO (JP) | 2023-05-17 | — | — | EP | claimed |
| EP-2376478-B1 | PYRIDYLOXYINDOLES INHIBITORS OF VEGF-R2 AND USE THEREOF FOR TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2017-04-19 | — | — | EP | claimed |
| EP-2632458-B1 | DOSING REGIMES FOR THE TREATMENT OF OCULAR VASCULAR DISEASE | NOVARTIS AG (CH) | 2015-08-12 | — | — | EP | claimed |
| EP-2632458-A1 | DOSING REGIMES FOR THE TREATMENT OF OCULAR VASCULAR DISEASE | Novartis AG (CH) | 2013-09-04 | — | — | EP | claimed |
| US-20130197016-A1 | DOSING REGIMES FOR THE TREATMENT OF OCULAR VASCULAR DISEASE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2013-08-01 | — | — | US | claimed |
| WO-2012055884-A1 | DOSING REGIMES FOR THE TREATMENT OF OCULAR VASCULAR DISEASE | NOVARTIS AG (CH) | 2012-05-03 | — | — | WO | claimed |
| CN-1019397-B | The method for preparing diphosphonic acid derivative | YAMANOUCHI PHARMA CO LTD (JP) | 1992-12-09 | — | — | CN | claimed |
| CN-88102021-A | Diphosphonic acid derivative and contain the medicine of this derivative | — | 1988-10-05 | — | — | CN | claimed |
| US-20230101819-A1 | SMYD Inhibitors | EPIZYME INC (US) | 2023-03-30 | — | — | US | disclosed |
| US-20210198252-A1 | SMYD INHIBITORS | EPIZYME INC (US) | 2021-07-01 | — | — | US | disclosed |
| EP-3193604-B1 | SUBSTITUTED N-(PYRROLIDIN-3-YL)ISOXAZOLE-3-CARBOXAMIDE COMPOUNDS | EPIZYME INC (US) | 2021-06-16 | — | — | EP | disclosed |
| US-20200148650-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS | Epizyme, Inc. | 2020-05-14 | — | — | US | disclosed |
| US-10577363-B2 | Substituted piperidine compounds | Epizyme, Inc. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190322660-A1 | SMYD INHIBITORS | Epizyme, Inc. | 2019-10-24 | — | — | US | disclosed |
| US-20120245187-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2012-09-27 | — | — | US | disclosed |
| US-8242125-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2012-08-14 | — | — | US | disclosed |
| WO-2012055884-A1 | DOSING REGIMES FOR THE TREATMENT OF OCULAR VASCULAR DISEASE | NOVARTIS AG (CH) | 2012-05-03 | — | — | WO | disclosed |
| US-20120101031-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20100168082-A1 | Heterobicyclic Carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2010-07-01 | — | — | US | disclosed |
| WO-2010066684-A2 | Pyridyloxyindoles Inhibitors of VEGF-R2 and Use Thereof for Treatment of Disease | NOVARTIS AG (CH) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101031-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS15, PRSS1, SPINT2 | S1PR3 511/4885S1PR1 704/4885NPC1 100/4885 |
| US-10577363-B2 | Substituted piperidine compounds | SMYD3, SMYD2, SNRPD3 | S1PR3 91/4885S1PR1 222/4885NPC1 2214/4885 |
| US-20120245187-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | CDK2, PHKG1, PHKG2 | S1PR3 2755/4885S1PR1 2741/4885NPC1 4183/4885 |
| US-20210198252-A1 | SMYD INHIBITORS | SMYD3, SMYD2, SMURF2 | S1PR3 1458/4885S1PR1 2423/4885NPC1 3734/4885 |
| US-20190322660-A1 | SMYD INHIBITORS | SMYD2, SMYD3, SMURF2 | S1PR3 1395/4885S1PR1 2216/4885NPC1 3830/4885 |
| US-20100168082-A1 | Heterobicyclic Carboxamides as inhibitors for kinases | CDK2, PHKG1, PHKG2 | S1PR3 2755/4885S1PR1 2741/4885NPC1 4183/4885 |
| US-20200148650-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS | SMYD3, SMYD2, SNRPD3 | S1PR3 1484/4885S1PR1 2906/4885NPC1 3842/4885 |
| US-20230101819-A1 | SMYD Inhibitors | SMYD3, SMYD2, SMURF2 | S1PR3 1388/4885S1PR1 2362/4885NPC1 3716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.